The impact of treatment modality and radiation technique on outcomes and toxicity of patients with locally advanced oropharyngeal cancer

Laryngoscope

Volumn 123, Issue 2, 2013, Pages 386-393

  Al Mamgani, Abrahim ^a   Van Rooij, Peter ^a   Verduijn, Gerda M ^a   Mehilal, Robert ^a   Kerrebijn, Jeroen D ^a   Levendag, Peter C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

head and neck cancer; IMRT; Level of Evidence: 2c; locally advanced; Oropharyngeal cancer; toxicity

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DERMATITIS; DISEASE FREE SURVIVAL; DYSPHAGIA; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TOXICITY; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84873684976     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23699     Document Type: Article

References (15)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. J Cancer 2010; 46: 765-81.
2. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-55. (Pubitemid 30148259)
3. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
4. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-36.
5. Hodge CW, Bentzen SM, Wong G, et al. Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. Int J Radiat Oncol Biol Phys 2007; 69: 1032-41. (Pubitemid 47625846)
6. Rusthoven KE, Raben D, Ballonoff A, et al. Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope 2008; 118: 635-9. (Pubitemid 351496757)
7. Dirix P, Nuyts S,. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010; 78: 1373-1380.
8. Al-Mamgani A, Tans L, Teguh DN, et al. Stereotactic body radiotherapy: a promising treatment option for the boost of oropharyngeal cancers not suitable for brachytherapy: a single-institutional experience. Int J Radiat Oncol Biol Phys 2012; 82: 1494-1500.
9. Raktoe SA, Dehnad H, Raaijmakers CP, et al. Origin of tumor recurrence after intensity modulated radiation therapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2012. In Press.
10. Hitt R, Lopez A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-45. (Pubitemid 46211506)
11. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
12. Horsman MR, Overgaard J,. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol) 2007; 6: 418-26. (Pubitemid 46995618)
13. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: A dose-effect relationship. Radiother Oncol 2007; 85: 64-73. (Pubitemid 47562584)
14. Schwartz DL, Hutcheson K, Barringer D, et al. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78: 1356-65.
15. Little M, Schipper M, Feng FY, et al. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 2012; 83: 1007-14.